Novartis Stock Screener | Share Price & Fundamental Analysis
NOVARTIND
Pharmaceuticals
Share Price BSE
₹1001.65
▲
1.55 (0.15%)
Track Novartis share price live with TickJournal's free stock screener.
Analyze Novartis share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Novartis Market Cap
₹2,537.55 Cr.
NOVARTIND P/E Ratio (TTM)
25.75
Novartis P/B Ratio
3.23
EPS (TTM)
₹40.87
Dividend Yield
2.46%
Debt to Equity
0.01
NOVARTIND 52 Week High
₹1081.55
Novartis 52 Week Low
₹759.30
Operating Margin
28.00%
Profit Margin
25.06%
NOVARTIND Revenue (TTM)
₹387.00
EBITDA
₹137.00
Net Income
₹97.00
Total Assets
₹948.00
Total Equity
₹785.00
Novartis Share Price History - Stock Screener Chart
Screen NOVARTIND historical share price movements with interactive charts. Analyze price trends and patterns.
Novartis Company Profile - Fundamental Screener
Screen Novartis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NOVARTIND shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE234A01025
Novartis Balance Sheet Screener
Screen NOVARTIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 948 | 925 | 983 | 958 | 1,002 | 1,078 | 982 | 1,111 | 1,150 | 1,433 |
| Current Assets | 746 | 699 | 677 | 709 | 723 | 813 | 807 | 952 | 973 | 1,264 |
| Fixed Assets | 5 | 7 | 19 | 24 | 64 | 76 | 15 | 5 | 6 | 7 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 21 | 23 | 48 | 50 | 132 | 124 | 38 | 47 | 47 | 35 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 785 | 745 | 776 | 692 | 711 | 721 | 759 | 734 | 920 | 1,194 |
| Share Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 | 16 |
| Reserves & Surplus | 773 | 733 | 763 | 679 | 699 | 708 | 747 | 721 | 906 | 1,178 |
Novartis Income Statement Screener - Profit & Revenue Analysis
Screen Novartis income statement and profit fundamentals.
Analyze NOVARTIND quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Novartis share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 387 | 398 | 397 | 437 | 433 | 414 | 474 | 569 | 736 | 727 | 771 | 981 |
| Expenses | 250 | 265 | 270 | 314 | 373 | 355 | 426 | 478 | 570 | 631 | 656 | 877 |
| EBITDA | 137 | 133 | 127 | 123 | 60 | 60 | 48 | 91 | 166 | 96 | 115 | 104 |
| Operating Profit % | 28.00% | 26.00% | 19.00% | 17.00% | 7.00% | 7.00% | 3.00% | 3.00% | -1.00% | 4.00% | 5.00% | 0.00% |
| Depreciation | 2 | 2 | 3 | 6 | 10 | 12 | 13 | 3 | 3 | 4 | 4 | 4 |
| Interest | 1 | 1 | 2 | 2 | 5 | 8 | 6 | 2 | 6 | 1 | 0 | 0 |
| Profit Before Tax | 133 | 130 | 123 | 115 | -4 | 40 | 29 | 86 | 158 | 92 | 111 | 93 |
| Tax | 36 | 30 | 38 | 12 | 0 | 19 | 19 | 34 | 79 | 35 | 39 | 14 |
| Net Profit | 97 | 101 | 85 | 103 | -4 | 21 | 10 | 52 | 78 | 57 | 73 | 79 |
| EPS | 39.40 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.10 | 62.04 | 24.75 |
Novartis Cash Flow Screener - Liquidity Fundamentals
Screen NOVARTIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 75 | 113 | 45 | 39 | -69 | -23 | -194 | 161 | -41 | 57 |
| Investing Activities | -3 | 33 | -153 | 87 | 95 | 56 | 274 | 69 | 424 | -631 |
| Financing Activities | -64 | -121 | -31 | -36 | -37 | -41 | -30 | -268 | -332 | -39 |
| Net Cash Flow | 7 | 26 | -139 | 90 | -11 | -9 | 50 | -38 | 51 | -613 |
Novartis Shareholding Pattern Screener
See Novartis shareholding pattern with promoter, FII, and DII holdings.
Check Novartis promoter holding and ownership changes for NOVARTIND on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII Holding | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| DII Holding | 0.64% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.67% | 22.92% | 22.95% | 23.11% | 23.01% | 23.05% | 23.04% | 22.95% |
| Other Holding | 5.83% | 5.68% | 5.66% | 5.49% | 5.59% | 5.55% | 5.57% | 5.65% |
| Shareholder Count | 39,468 | 39,353 | 39,040 | 39,133 | 38,926 | 39,596 | 39,265 | 41,239 |
Novartis Share Dividend Screener - Share Yield Analysis
Check Novartis dividend history with payout and yield data.
View Novartis dividend details including ex-dates and amounts for NOVARTIND stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹25.00 | 2.58% |
| 2024-March | ₹25.00 | 3.18% |
| 2023-March | ₹47.50 | 4.62% |
| 2022-March | ₹10.00 | 1.76% |
| 2021-March | ₹10.00 | 1.69% |
| 2020-March | ₹10.00 | 1.81% |
| 2019-March | ₹10.00 | 1.99% |
| 2018-March | ₹10.00 | 1.46% |
| 2017-March | ₹10.00 | 1.63% |
Novartis Stock Index Membership
See which indices include Novartis stock.
Check NOVARTIND index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
Novartis Market Events Screener - Corporate Actions
Get Novartis corporate actions including splits, bonuses, and buybacks.
Check Novartis stock events that may affect NOVARTIND share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | 3.23% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | -3.77% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 24.87% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -0.92% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 25.00 /share | 33.11% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.94% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -4.09% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.21% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 11.66% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 25.00 /share | 5.99% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 10.00 /share | 32.63% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 37.50 /share | 32.63% |
| 2022-07-20 | 2022-07-22 | Dividend | ₹ 10.00 /share | 7.03% |
| 2021-08-17 | 2021-08-20 | Dividend | ₹ 10.00 /share | -11.14% |
Novartis Competitors Screener - Peer Comparison
Screen NOVARTIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Novartis Company Announcements - News Screener
Screen NOVARTIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-04 | Board Meeting Intimation for Intimation Of Meeting Of The Board Of Directors Of Novartis India Limited (The Company) And Closure Of Trading Window. | - |
| 2026-04-04 | Closure of Trading Window | - |
| 2026-04-03 | Intimation Of The Receipt Of Delhi High Court Order Admitting Company Petition In The Matter Of Novartis India Limited Vs. Commissioner Of Trade And Taxes (W.P.(C) 3892/2026) | - |
| 2026-03-31 | Intimation Under Reg 30 Of SEBI LODR Of Receipt Of TDS Order As Per Income Tax Act | - |
| 2026-03-31 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-31 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-03-31 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-31 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited (The Company) Held Today I.E. Friday March 27 2026. | - |
| 2026-03-06 | Intimation Of Receipt Of Draft Letter Of Offer Received From Manager To Open Offer (Axis Capital Limited). | - |
| 2026-03-06 | Draft Letter of Offer | - |
| 2026-02-26 | Detailed Public Statement | - |
| 2026-02-26 | Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer | - |
| 2026-02-20 | Open Offer - Public Announcement | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
| 2026-01-29 | Rumour verification - Regulation 30(11) | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-28 | Integrated Filing (Financial) For The Quarter Ended December 31 2025. | - |
| 2026-01-28 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited (The Company) Held On Wednesday January 28 2026. | - |